Vitality Watch

Dossier pubmed review 11-sep-2026
Narrative review or expert overview without new data

Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.

Key claim: Mitochondrial dysfunction is a unifying pathogenic driver across osteoporosis, osteoarthritis, and rheumatoid arthritis, and matching specific mitochondrial defects to targeted interventions may enable disease-modifying musculoskeletal therapies.

Abstract

Musculoskeletal disorders (MSDs), including osteoporosis (OP), osteoarthritis (OA), and rheumatoid arthritis (RA), represent a stubborn burden in modern medicine. They share a breakdown in mitochondrial homeostasis. Mitochondrial dysfunction serves as a central pathogenic mechanism unifying these conditions and driving a paradigm shift from symptomatic management to mechanism-based therapeutic strategies. In this review, we examine how mitochondrial defects affect key cell types in bone, cartilage, and muscle, including osteoblasts, osteocytes, osteoclasts, chondrocytes, and skeletal muscle cells, with a focus on osteoporosis (OP), osteoarthritis (OA), and rheumatoid arthritis (RA) as the three primary musculoskeletal conditions that share mitochondrial dysfunction as a unifying mechanism. Impaired energy production, altered dynamics, defective quality control, and redox imbalance each contribute to disease progression. These disturbances drive oxidative damage, metabolic reprogramming, impaired mitophagy, and the release of pro-inflammatory signals known as mtDAMPs. Importantly, such defects are not irreversible, we further synthesize the emerging landscape of mitochondria-targeted strategies. These include antioxidants like MitoQ and SkQ1, metabolic modulators such as metformin and NAD⁺ boosters, mitophagy inducers like urolithin A, fission inhibitors including Mdivi-1, senolytic agents, and even mitochondrial transplantation. We conclude by proposing a precision medicine framework that matches specific mitochondrial abnormalities with mechanism-based interventions. Drawing on recent preclinical and clinical evidence, this review positions mitochondrial crosstalk as a promising foundation for developing disease-modifying therapies in musculoskeletal medicine.

Why this matters

Mitochondrial transplantation is being pulled into the broader ‘mitochondrial homeostasis’ umbrella that reviewers are now using to unify osteoporosis, osteoarthritis, and rheumatoid arthritis — a framing that lets a still-preclinical technique ride alongside better-established interventions like metformin, urolithin A, and senolytics in the same therapy landscape table. The trend signal here is the packaging: a review-level synthesis can make a mechanism-plausible intervention read as clinic-ready when the underlying human outcome evidence has not moved.

Source

Link

Briefing card

Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.
Stage: review · pubmed · 11-sep-2026

If you take mitochondrial supplements (urolithin A, NAD+ precursors, MitoQ, CoQ10, metformin) for joint or bone health, this review sorts them by which mitochondrial defect they target but adds no human MSK outcome data.

Mitochondrial dysfunction is a unifying pathogenic driver across osteoporosis, osteoarthritis, and rheumatoid arthritis, and matching specific mitochondrial defects to targeted interventions may enable disease-modifying musculoskeletal therapies.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.phrs.2026.108441

build build 880 · 2bcef25 · 2026-11-18